{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:55:49Z","timestamp":1785045349268,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatric.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.cger.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T21:33:13Z","timestamp":1587072793000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Diabetes and Heart Failure"],"prefix":"10.1016","volume":"36","author":[{"given":"Adi","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeeb","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Estep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Faiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2020.04.005_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035.","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cger.2020.04.005_bib2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrendo.2016.105","article-title":"Diabetes mellitus statistics on prevalence and mortality: facts and fallacies","volume":"12","author":"Zimmet","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.cger.2020.04.005_bib3","first-page":"e38","article-title":"Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association","volume":"133","author":"Mozzafarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2020.04.005_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of diabetes on epidemiology, treatment and outcomes of patients with heart failure.","volume":"3","author":"Dei Cas","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cger.2020.04.005_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/07853890.2012.660493","article-title":"Update on diastolic heart failure or heart failure with preserved ejection in the older adults.","volume":"45","author":"Alagiakrishnan","year":"2013","journal-title":"Ann Med"},{"key":"10.1016\/j.cger.2020.04.005_bib6","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study.","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2020.04.005_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated ith diabetic glomerulosclerosis.","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cger.2020.04.005_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure; findings from Get With The Guidelines\u2013Heart Failure registry.","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.cger.2020.04.005_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.294.3.334","article-title":"Insulin resistance and risk of congestive heart failure","volume":"294","author":"Ingelsson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2020.04.005_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2013an engine out of fuel.","volume":"356","author":"Neubauer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2020.04.005_bib11","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/01.CIR.98.20.2180","article-title":"Additive effects of hyperinsulinemia and ischemia on myocardial GLUT 1 and GLUT 4 translocation in vivo","volume":"98","author":"Russell","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2020.04.005_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/ars.2006.1458","article-title":"Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications","volume":"9","author":"Nishikawa","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.cger.2020.04.005_bib13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","article-title":"Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study","volume":"116","author":"McGavock","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2020.04.005_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart. Importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2020.04.005_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0735-1097(99)00168-0","article-title":"Hyperglycemia rapidly suppresses flow mediated endothelium dependent vasodilatation of brachial artery","volume":"34","author":"Kawano","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2020.04.005_bib16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/dc11-0034","article-title":"Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients","volume":"34","author":"DiFlavian","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cger.2020.04.005_bib17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: sparking the development of diabetic vascular injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2020.04.005_bib18","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"35","author":"Seferovic","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cger.2020.04.005_bib19","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1007\/s00125-012-2681-3","article-title":"The relationship between glycemic control and heart failure in 83021 patients with type 2 diabetes","volume":"55","author":"Lind","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.cger.2020.04.005_bib20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetes, evidence from a 37,229 patient meta-analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cger.2020.04.005_bib21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.jacc.2018.08.2160","article-title":"Lifestyle modifications for preventing and treating heart failure","volume":"72","author":"Aggarwal","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2020.04.005_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure or chronic liver disease: a systemic review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cger.2020.04.005_bib23","doi-asserted-by":"crossref","first-page":"e1001204","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.cger.2020.04.005_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"3","author":"Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cger.2020.04.005_bib25","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cger.2020.04.005_bib26","doi-asserted-by":"crossref","first-page":"e005379","DOI":"10.1161\/JAHA.116.005379","article-title":"Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study","volume":"6","author":"Roumie","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cger.2020.04.005_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2261-14-129","article-title":"The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies","volume":"14","author":"Varas-Lorenzo","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cger.2020.04.005_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ejheart.2008.05.013","article-title":"The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy","volume":"10","author":"McAlister","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cger.2020.04.005_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive trial","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.cger.2020.04.005_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12872-016-0260-0","article-title":"Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systemic review and meta-analysis of randomized and observational studies","volume":"16","author":"Li","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cger.2020.04.005_bib31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide 1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.cger.2020.04.005_bib32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2020.04.005_bib33","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cger.2020.04.005_bib34","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2020.04.005_bib35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2020.04.005_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of depagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cger.2020.04.005_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cger.2020.04.005_bib38","first-page":"973","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"382","author":"McMurray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2020.04.005_bib39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","article-title":"Direct cardiovascular impact of SGLT-2 inhibitor: mechanisms and effects","volume":"23","author":"Kaplan","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cger.2020.04.005_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S2213-8587(13)70027-5","article-title":"Intensive insulin for type 2 diabetes: the risk of causing harm","volume":"1","author":"Nolan","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cger.2020.04.005_bib41","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1136\/bmj.i3477","article-title":"Diabetes treatments and risk of heart failure, cardiovascular disease and all cause mortality: cohort study in primary care","volume":"354","author":"Hippislet-Coc","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cger.2020.04.005_bib42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2020.04.005_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.117.030924","article-title":"Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalizations: the ORIgiN trial","volume":"37","author":"Gerstein","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2020.04.005_bib44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec verses glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2020.04.005_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-0033-1363684","article-title":"Macro- and microvascular outcomes in patients with type 2 diabetes treated with rapid-acting insulin analogues or human regular insulin: a retrospective database analysis","volume":"122","author":"Rathmann","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"18","key":"10.1016\/j.cger.2020.04.005_bib46","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cger.2020.04.005_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4158\/EP161309.RA","article-title":"The impact of cardiovascular drugs on diabetes: a review","volume":"23","author":"Grodzinsky","year":"2017","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.cger.2020.04.005_bib48","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.cger.2020.04.005_bib49","first-page":"333","article-title":"Effect of sacubatril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069020300252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069020300252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:55:24Z","timestamp":1760061324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069020300252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0749069020300252"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2020.04.005","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes and Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Clinics in Geriatric Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cger.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}